CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.

about

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.

Item

http://www.wikidata.org/entity/Q55280859

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.

@en

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.

@nl

type

Item

label

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.

@en

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.

@nl

prefLabel

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.

@en

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.

@nl

P1476

CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment.

@en

P2093

G V Ramesh Prasad

http://www.w3.org/2001/XMLSchema#string

Lucy Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients

PharmGKB summary: cyclosporine and tacrolimus pathways

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.

The human CYP3A subfamily: practical considerations.

Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling

Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: a systematic review.

Calcineurin inhibitor nephrotoxicity.

Capability of utilizing CYP3A5 polymorphisms to predict therapeutic dosage of tacrolimus at early stage post-renal transplantation.

P304

23-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/PGPM.S107710

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29563827

http://www.w3.org/2001/XMLSchema#string

P932

5846312

http://www.w3.org/2001/XMLSchema#string